Cost-effectiveness analysis of metronomic capecitabine as adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma

Overview of attention for article published in Frontiers in oncology, September 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 8 Dimensions

Readers on

mendeley: 3 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 23,820 followers.

Cost-effectiveness analysis of metronomic capecitabine as adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma https://t.co/dLPO7DWr55 https://t.co/P8qZmP2Z9k

30 Sep 2022

Reply Repost Favourite

Cost-effectiveness analysis of metronomic capecitabine as adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Background, Adding metronomic capecitabine to concurrent chemoradiotherapy (CCRT) brings… #oncology https://t.co/89L4G2cqXB

14 Sep 2022

Reply Repost Favourite

New research: Cost-effectiveness analysis of metronomic capecitabine as adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Background Adding metronomic capecitabine to concurrent chemoradiotherapy (CCRT) brings… https://t.co/VEKsBQ

14 Sep 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.